Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Peter Impey

- PMLiVE

Ipsen enters $900m licensing agreement for Sutro Biopharma’s ADC candidate

STRO-003 will be the first ADC candidate to be added to Ipsen’s portfolio

- PMLiVE

Gilead gains rights to Xilio’s early-stage solid tumour candidate in deal worth up to $647.5m

XTX301 is currently being evaluated in a phase 1 trial in patients with advanced solid tumours

- PMLiVE

Researchers identify early treatment strategy for diabetic patients at risk of kidney disease

The chronic disease is currently the leading cause of kidney failure in the UK

- PMLiVE

Single genetic test could replace current standard for diagnosing rare developmental disorders

The single genetic test could potentially replace the current standard and reduce costs for the NHS

- PMLiVE

Enhancing collaborative decision-making for patients with MS

Optimising MS care and patient outcomes through advancing shared decision-making

- PMLiVE

Clinical Trial Protocol Conceptualization: A Customer Story

To set their Phase II clinical trial of a novel anti-cancer compound up for success, our client sought early multidisciplinary insights on current unmet needs, as well as feedback on their preclinical...

Impetus Digital

- PMLiVE

Merck’s Keytruda regimen granted EC approval for expanded lung cancer use

The approval represents the sixth lung cancer indication for the anti-PD-1 therapy in Europe

- PMLiVE

Indegene announces acquisition of Trilogy Writing & Consulting

The deal is aimed at increasing Indegene’s clinical and regulatory writing expertise for global market authorisation applications

- PMLiVE

PMLiVE’s T40 – open for submissions!

Healthcare agencies can submit their entries free of charge with a deadline of 30 April

- PMLiVE

FDA grants Invivyd’s Pemgarda emergency use authorisation for COVID-19 prevention

The long-acting monoclonal antibody is authorised for use in adults and adolescents

- PMLiVE

Teva UK and Closed Loop Medicine partner to advance development of personalised medicines

The collaboration will utilise Closed Loop Medicine’s software as a medical device technology platform

- PMLiVE

dna Communications appoints Niamh Mangan as executive vice president and managing director

Mangan joins from 90TEN, where she most recently served as managing director

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links